Eli Lilly (NYSE: LLY) is scheduled to report second-quarter results before the market opens on Wednesday, Aug. 5, with ...

Eli Lilly's key catalyst for 2027 could positively affect price action sooner than you think.

And it will likely be the first company in the sector to get there.

Eli Lilly will make experimental retatrutide available before FDA approval to a limited group. The eligibility bar is high.

The healthcare stock is up over 300% in five years and has a market cap of around $1 trillion.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company's (Lilly) olomorasib as a potential treatment for adults with advan ...

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A ...

Twelve years ago, Christian Angermayer took a mushroom trip that inspired him to try to create FDA-approved medicines from ...

As the $1 trln drugmaker’s smash-hit obesity treatments shrink waistlines, its ​cashflow and valuation are ​swelling. Gilead, ...

Sanofi (SNY) and Eli Lilly (LLY)-backed Scribe Therapeutics (SCTX) stock surges nearly 50% after an upsized IPO that raised ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q1 2026 investor letter. A copy of the letter can be ...